Back to News
Market Impact: 0.2
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Patients taking Vafseo (vadadustat) reached approximately 11,500 at the end of Q3 2026, up approximately 140% from the end of Q3 2025. The update indicates substantial year-over-year growth in the patient base; no revenue, profit, or market reaction was reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook